Skip to main content

Discontinuation Notice: Levemir Products to be Discontinued from January 2024

Medically reviewed by Judith Stewart, BPharm. Last updated on Jan 30, 2024.

November 8, 2024 -- Due to global manufacturing constraints, formulary losses impacting patient access, and the availability of alternative options, Novo Nordisk will be discontinuing Levemir® in the U.S.

The company will continue to provide Levemir® FlexPen® and Levemir® vials to wholesalers while supplies last, up to the discontinuation dates, but supply disruptions should be expected.

  • Mid-January 2024: Supply disruptions of Levemir® FlexPen®
  • April 1, 2024: Discontinuation of Levemir® FlexPen®
  • December 31, 2024: Full brand discontinuation, including Levemir® vial

Novo Nordisk's top priority is always the health and safety of the patients that use our products. The company made this decision after careful consideration, and is confident that patients will be able to access alternative treatments in the U.S.

The company recommends that healthcare providers talk to their patients about alternative treatment options in advance of this supply disruption and discontinuation to ensure continuity of care.

Source: Novo Nordisk

Reference: Levemir Product Information

Posted November 2023

Read this next

AI-Informed Health App Aids Diabetes Outcomes

WEDNSDAY, May 15, 2024 -- Use of an artificial intelligence (AI)-informed health app aids diabetes outcomes and cuts atherosclerotic cardiovascular disease (ASCVD) risk, according...

Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist

TUESDAY, May 14, 2024 -- One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using...

Fat-Enlarged Axillary Nodes on Mammogram May Indicate Higher CVD Risk

TUESDAY, May 14, 2024 -- Fat-enlarged axillary nodes on screening mammograms can predict the risk for cardiovascular disease (CVD), according to a study presented at the annual...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.